Type 1 diabetes and T regulatory cells.

Area of Science:

• Immunology
• Autoimmunity
• Cell Therapy

Background:

• T-regulatory cells (Tregs) are vital for maintaining peripheral immune tolerance.
• Dysfunctional or deficient Tregs are implicated in autoimmune diseases such as type 1 Diabetes (T1D).
• Conversely, excessive Tregs can suppress anti-cancer and anti-pathogen immunity.

Purpose of the Study:

• To review the role of Tregs in autoimmune diseases, with a specific focus on T1D.
• To highlight advancements and remaining obstacles in developing Treg-based therapeutic strategies for T1D.

Main Methods:

• Review of existing literature on Treg function in autoimmunity.
• Analysis of preclinical (animal models) and clinical (human) studies related to T1D.
• Discussion of challenges in Treg phenotype identification and therapeutic translation.

Main Results:

• Treg manipulation in animal models effectively reduces autoimmune pathology.
• T1D interventions explore Treg proliferation and adoptive transfer (in vitro and in vivo).
• Significant challenges remain, including Treg marker specificity and reconciling animal data with human outcomes.

Conclusions:

• Tregs are critical in controlling autoimmunity, particularly in T1D.
• Developing effective Treg-based therapies for T1D requires addressing current scientific and clinical hurdles.
• Further research is needed to refine Treg identification and ensure therapeutic efficacy and safety in humans.